Induced pluripotent stem cells, or iPS cells, are adult cells that have been reprogrammed back to a pluripotent state, which means they can form almost any cell type in the body. Shinya Yamanaka's team at Kyoto University reported them in 2006, and Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon. In March 2026 Japan granted conditional, time-limited approval to two products made from iPS-derived cells. This page explains how iPS cells were made, how they differ from embryonic stem cells, and where they stand in medicine now.

How iPS cells were made

In August 2006, Kazutoshi Takahashi and Shinya Yamanaka reported in the journal Cell that they had induced pluripotent stem cells from mouse embryonic and adult fibroblasts by introducing four factors: Oct3/4, Sox2, c-Myc and Klf4. The cells were grown under embryonic stem cell culture conditions. They resembled embryonic stem cells in morphology, growth and marker gene expression, and they formed tumors containing tissues from all three germ layers when transplanted into mice.

In November 2007, the same group reported iPS cells from adult human dermal fibroblasts, using the same four factors. The human cells were similar to human embryonic stem cells in morphology, proliferation, surface antigens, gene expression and telomerase activity, and they could differentiate into cell types of all three germ layers.

These four proteins are now called the Yamanaka factors. They are transcription factors, proteins that control which genes a cell switches on.

The Nobel Prize

In 2012, the Nobel Prize in Physiology or Medicine was awarded jointly to Sir John B. Gurdon and Shinya Yamanaka "for the discovery that mature cells can be reprogrammed to become pluripotent." Gurdon's earlier work had shown that specialized cells can be reprogrammed. Yamanaka's contribution was to show that a small set of defined factors is enough to do this in cultured cells.

A person in a white lab coat and gloves looking through a microscope beside an open laptop in a laboratory.

How iPS cells differ from embryonic stem cells

Embryonic stem cells come from early embryos, and obtaining them involves destroying the embryo. That is the main ethical objection. iPS cells are made from adult cells, such as skin or blood cells, so no embryo is needed.

iPS cells can also be made from a specific person's cells. This raises the possibility of using a patient's own cells, which may reduce the immune rejection risk that donor cells carry. But iPS cells carry their own problems. The 2006 mouse work showed tumor formation after transplantation. Incomplete differentiation, leftover undifferentiated cells, and changes introduced during reprogramming all raise the risk of tumors, and that risk has to be controlled in any clinical use. Making patient-specific iPS cells also takes time and money, which is one reason some research groups have built donor cell banks.

Where iPS cells stand in medicine

On 6 March 2026, the Ministry of Health, Labour and Welfare (MHLW) granted conditional, time-limited approval to two iPS cell-derived products. One is リハート (Cuorips), made from donor iPS-derived heart muscle cells and used for severe heart failure caused by ischemic cardiomyopathy. The other is Amchepry (アムシェプリ), from Sumitomo Pharma, made from donor iPS-derived dopamine precursor cells and used for Parkinson's disease. The Japan Science and Technology Agency (JST) reports that these are the first iPS cell-derived regenerative medicine products approved anywhere in the world.

Two people in white lab coats work with glass flasks and test tubes in a laboratory.

Conditional approval means the MHLW judged that safety was confirmed and effectiveness could be presumed from a small number of cases. The company must confirm effectiveness through actual treatment within seven years before the product can receive full approval. Clinical trials behind the approvals were small: eight patients received the heart product, and seven received the Parkinson's product.

Other iPS-based projects are at the trial or clinical research stage. JST lists type 1 diabetes, traumatic spinal cord injury, aplastic anemia, age-related macular degeneration and corneal limbal stem cell deficiency. Most of these have strict enrollment criteria.

For Parkinson's specifically, see Stem Cell Therapy for Parkinson's Disease. For the approval itself, see Japan Approves the First iPS Cell–Derived Products.

Why the 2006 result mattered

Before 2006, the main route to pluripotent cells was embryonic stem cells, which come from embryos. Takahashi and Yamanaka showed that adult mouse fibroblasts could be pushed back toward a pluripotent state by four genes, without an embryo. The same paper tested what the cells could do. When they were transplanted into mice, they formed tumors containing tissue from all three germ layers. That showed the cells were pluripotent, and it also showed the tumor risk that any later clinical work has to control. The 2007 paper then reported the same four factors working on adult human dermal fibroblasts.

What to separate when you hear "iPS"

Advertising may use the word "iPS" for several different things. It helps to separate them:

A person in a white lab coat and blue gloves holding a pipette in a laboratory.

  1. Approved products, which are subject to pharmaceutical approval and have defined indications.
  2. Trials and clinical research, which have enrollment criteria set by the research team.
  3. Treatments under a filed plan, which are self-pay services under Japan's regenerative medicine Act. A filed plan shows that legal steps were taken. It is not proof that the treatment works.
  4. Products labeled "iPS" that do not contain transplanted cells, such as culture-derived exosome products. The Japanese Society for Regenerative Medicine warned in December 2024 that clinical evidence for iPS-derived exosome treatments, including for anti-aging, has not been established.

For how Japan's system is organized, see how Japan regulates regenerative medicine. If you are considering a treatment that uses iPS cells, send the clinic's name and the treatment name to our advisors, and we will check whether it has filed a provision plan for that treatment.

Frequently asked questions

What is the difference between iPS cells and ordinary stem cells?

iPS cells are pluripotent, so in principle they can form almost any cell type. Adult stem cells used in clinics, such as fat-derived or cord-derived mesenchymal cells, have a narrower range of cell types.

Can I receive iPS cell treatment in Japan now?

The range is narrow. The two approved products are limited to specific conditions. Other iPS-based work is in trials or clinical research, where enrollment is limited.

Is an "iPS exosome" treatment the same as iPS cell therapy?

No. Exosome products are made from culture fluid and do not transplant cells. The Japanese Society for Regenerative Medicine says their clinical evidence is not yet established.

Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.


Sources: Takahashi and Yamanaka, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors," Cell 126 (2006), PubMed 16904174; Takahashi et al., "Induction of pluripotent stem cells from adult human fibroblasts by defined factors," Cell 131 (2007), PubMed 18035408; Nobel Prize, 2012 Prize in Physiology or Medicine summary; Japan Science and Technology Agency (JST) Science Portal, 18 March 2026; Japanese Society for Regenerative Medicine, notice on iPS cell-derived exosomes, 27 December 2024. Checked November 2026; MHLW and JST publications prevail.

Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.